Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SPERM.STthis companySpermosens AB	SEK 0.01	-1.61×	0.45×	0×	-0.87×	-67.3%	0.0%	0.0%	0.0%	-28.4%	-28.5%	-83.9%	0×	0.75×	0×	5.1×	0.0%	1	12.11	2	C
APTA.STAptahem AB (publ)	SEK 0.27	-3.71×	0.36×	0×	-3.38×	-44.2%	0.0%	0.0%	0.0%	-9.6%	-9.6%	-40.8%	0×	0.47×	0×	2.93×	0.0%	2	2.08	2	C+
EPIS-B.STEpisurf Medical AB	SEK 0.06	-0.63×	0.77×	2.71×	-0.74×	-817.4%	-429.6%	-447.4%	-431.1%	-122.5%	-115.3%	-169.4%	0.14×	0.01×	-100.67×	1.7×	0.0%	4	-0.62	2	C
FLUI.STFluicell AB (publ)	SEK 27.70	-1.65×	1.26×	2.29×	-1.38×	-381.5%	-144.7%	-144.7%	-138.8%	-76.4%	-79.7%	-99.1%	0×	0.27×	-45×	1×	0.0%	3	-3.05	3	B+
ODI.STODI Pharma AB	SEK 1.33	21.82×	18.52×	1.34×	15.65×	-2478.3%	31.2%	7.6%	6.0%	83.7%	105.4%	10.4%	0×	-1.31×	4.15×	1.81×	0.0%	6	13.25	3	B-
PROGEN.STProstatype Genomics AB (publ)	SEK 0.10	-0.23×	0.38×	17.06×	-0.17×	-371.4%	-6332.7%	-6579.1%	-7492.1%	-167.8%	-122.8%	-237.4%	0.2×	0.1×	-24.2×	0.44×	0.0%	2	-3.97	2	C
Peer median	—	-0.63×	0.77×	2.29×	-0.74×	-381.5%	-144.7%	-144.7%	-138.8%	-76.4%	-79.7%	-99.1%	0×	0.1×	-24.2×	1.7×	0.0%	3	-0.62	2	—